Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
Emerging Technology Trends in Biopharma The intersection of technology and biopharma isn’t a futuristic idea anymore it’s happening right now. Artificial intelligence (...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
Key Highlights: Implications: PrecisionCHD taps India’s $1.5B+ cardiac diagnostics market (15% CAGR), challenging ECG/stress tests via molecular insights and Dr Lal’s netw...
